BrainCheck - a very brief tool to detect incipient cognitive decline: optimized case-finding combining patient- and informant-based data.

INTRODUCTION Optimal identification of subtle cognitive impairment in the primary care setting requires a very brief tool combining (a) patients' subjective impairments, (b) cognitive testing, and (c) information from informants. The present study developed a new, very quick and easily administered case-finding tool combining these assessments ('BrainCheck') and tested the feasibility and validity of this instrument in two independent studies. METHODS We developed a case-finding tool comprised of patient-directed (a) questions about memory and depression and (b) clock drawing, and (c) the informant-directed 7-item version of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). Feasibility study: 52 general practitioners rated the feasibility and acceptance of the patient-directed tool. Validation study: An independent group of 288 Memory Clinic patients (mean ± SD age = 76.6 ± 7.9, education = 12.0 ± 2.6; 53.8% female) with diagnoses of mild cognitive impairment (n = 80), probable Alzheimer's disease (n = 185), or major depression (n = 23) and 126 demographically matched, cognitively healthy volunteer participants (age = 75.2 ± 8.8, education = 12.5 ± 2.7; 40% female) partook. All patient and healthy control participants were administered the patient-directed tool, and informants of 113 patient and 70 healthy control participants completed the very short IQCODE. RESULTS Feasibility study: General practitioners rated the patient-directed tool as highly feasible and acceptable. Validation study: A Classification and Regression Tree analysis generated an algorithm to categorize patient-directed data which resulted in a correct classification rate (CCR) of 81.2% (sensitivity = 83.0%, specificity = 79.4%). Critically, the CCR of the combined patient- and informant-directed instruments (BrainCheck) reached nearly 90% (that is 89.4%; sensitivity = 97.4%, specificity = 81.6%). CONCLUSION A new and very brief instrument for general practitioners, 'BrainCheck', combined three sources of information deemed critical for effective case-finding (that is, patients' subject impairments, cognitive testing, informant information) and resulted in a nearly 90% CCR. Thus, it provides a very efficient and valid tool to aid general practitioners in deciding whether patients with suspected cognitive impairments should be further evaluated or not ('watchful waiting').

Attention affects prospective memory performance in dichotic listening paradigm

The current study was designed to test for the effect of lateralized attention on prospective memory performance in a dichotic listening task. The practice phase of the experiment consisted of a semantic decision task during which the participants were presented with different words on either side via headphones. Depending on the experimental condition the participants were required to focus on the words presented on the left or right side and to decide if these words were abstract or concrete. Thereafter, the participants were informed about the prospective memory task. They were instructed to press a distinct key whenever they hear a word which denotes an animal in the same task later during the experiment. The participants were explicitly informed that the prospective memory cues could appear on either side of the headphones. This was followed by a retention interval which was filled with unrelated tasks. Next, the participants performed the prospective memory task. The results revealed more prospective hits for the attended side. The finding suggests that noticing a prospective memory cue is not an automatic process but requires attention.

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

UNLABELLED Early assessment of response at 3 months of tyrosine kinase inhibitor treatment has become an important tool to predict favorable outcome. We sought to investigate the impact of relative changes of BCR-ABL transcript levels within the initial 3 months of therapy. In order to achieve accurate data for high BCR-ABL levels at diagnosis, beta glucuronidase (GUS) was used as a reference gene. Within the German CML-Study IV, samples of 408 imatinib-treated patients were available in a single laboratory for both times, diagnosis and 3 months on treatment. In total, 301 of these were treatment-naïve at sample collection. RESULTS (i) with regard to absolute transcript levels at diagnosis, no predictive cutoff could be identified; (ii) at 3 months, an individual reduction of BCR-ABL transcripts to the 0.35-fold of baseline level (0.46-log reduction, that is, roughly half-log) separated best (high risk: 16% of patients, 5-year overall survival (OS) 83% vs 98%, hazard ratio (HR) 6.3, P=0.001); (iii) at 3 months, a 6% BCR-ABL(IS) cutoff derived from BCR-ABL/GUS yielded a good and sensitive discrimination (high risk: 22% of patients, 5-year OS 85% vs 98%, HR 6.1, P=0.002). Patients at risk of disease progression can be identified precisely by the lack of a half-log reduction of BCR-ABL transcripts at 3 months.

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV

PURPOSE Deep molecular response (MR(4.5)) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after treatment discontinuation. It is unclear how many patients achieve MR(4.5) under different treatment modalities and whether MR(4.5) predicts survival. PATIENTS AND METHODS Patients from the randomized CML-Study IV were analyzed for confirmed MR(4.5) which was defined as ≥ 4.5 log reduction of BCR-ABL on the international scale (IS) and determined by reverse transcriptase polymerase chain reaction in two consecutive analyses. Landmark analyses were performed to assess the impact of MR(4.5) on survival. RESULTS Of 1,551 randomly assigned patients, 1,524 were assessable. After a median observation time of 67.5 months, 5-year overall survival (OS) was 90%, 5-year progression-free-survival was 87.5%, and 8-year OS was 86%. The cumulative incidence of MR(4.5) after 9 years was 70% (median, 4.9 years); confirmed MR(4.5) was 54%. MR(4.5) was reached more quickly with optimized high-dose imatinib than with imatinib 400 mg/day (P = .016). Independent of treatment approach, confirmed MR(4.5) at 4 years predicted significantly higher survival probabilities than 0.1% to 1% IS, which corresponds to complete cytogenetic remission (8-year OS, 92% v 83%; P = .047). High-dose imatinib and early major molecular remission predicted MR(4.5). No patient with confirmed MR(4.5) has experienced progression. CONCLUSION MR(4.5) is a new molecular predictor of long-term outcome, is reached by a majority of patients treated with imatinib, and is achieved more quickly with optimized high-dose imatinib, which may provide an improved therapeutic basis for treatment discontinuation in CML.

Mit Eco-Drive gegen Strassenlärm. Evaluation eines Interventionsprogramms zur Förderung eines leisen Fahrstils.

Strassenlärm ist diejenige Verkehrslärmquelle, die am meisten Menschen belastet. Veränderungen im Handeln der Lärmverursachenden stellen eine vielversprechende Möglichkeit dar, bisherige Lärmbekämpfungsmassnahmen zu ergänzen. Die vorliegende Studie, welche vom Schweizerischen Bundesamt für Umwelt und dem Ministerium für Umwelt, Landwirtschaft, Ernährung, Weinbau und Forsten Rheinland-Pfalz gefördert wurde, widmete sich der Frage, wie die Förderung eines leisen Fahrstils zur Bekämpfung von Strassenlärm nutzbar gemacht werden kann. Hierzu erarbeiteten wir ein Interventionsprogramm zur Förderung eines leisen Fahrstils, welches in Zusammenarbeit mit Mitarbeitenden einer Stadtverwaltung umgesetzt und evaluiert wurde. Die Ergebnisse dieser Studie deuten darauf hin, dass es sich lohnt, einen leisen Fahrstil im Rahmen der Lärmbekämpfung zu fördern; während der mehrwöchigen Durchführung des Programms konnte eine Reduktion der durchschnittlichen Drehzahl, des durchschnittlichen Treibstoffverbrauchs, des gemittelten Summenpegels des Motorengeräuschs wie auch der prozentualen Fahrzeit mit Motorengeräuschen über 60dB(A) beobachtet werden. Befragungen der TeilnehmerInnen gaben zudem Auskunft über die diesen Veränderungen zu Grunde liegende Motivstruktur. Wir präsentieren in diesem Bericht sowohl eine detaillierte Darstellung des verwendeten Interventionsprogramms, des Vorgehens bei dessen Evaluation, sowie die entsprechenden Auswertungen. Wir hoffen, dass durch diese Studie zukünftige Programme zur Förderung eines leisen Fahrstils angeregt werden und von unseren Ergebnissen profitieren können.